Hiring Senior Executives for Healthcare and Life Sciences: A Complete UK Guide

Healthcare and life sciences is one of the most distinctive sectors for UK senior hiring. Regulatory complexity, scientific and clinical depth, long product-development cycles, a crowded stakeholder map (regulators, payers, clinicians, patients and the NHS as a dominant buyer) and capital-intensive business models combine to produce leadership demands that have no direct parallel elsewhere. The sub-sector range is also broad — pharmaceuticals, medical devices, diagnostics, digital health, biotech, clinical research organisations, healthcare services, and NHS-adjacent commissioning and consultancy — and each sub-sector draws on a different candidate pool and operates under different regulatory and commercial conditions.

The appointments that work are the ones calibrated to the specific sub-sector from the start. A search briefed at the level of “we need a healthcare CEO” tends to produce a shortlist that looks credible on paper but mixes candidates whose experience does not transfer: a pharma commercial leader, a hospital group operator and a digital health founder are not interchangeable, even if all three have “healthcare” on their CV.

This guide is written for chairs, CEOs, founders, board members and investors approaching senior hiring at UK healthcare and life sciences businesses. It covers the major sub-sectors, the regulatory dimensions, the policy changes now reshaping the market, the senior team typically required, the candidate pool, compensation, and the common pitfalls. For our search service itself, see healthcare and life sciences executive recruitment.

The major UK healthcare and life sciences sub-sectors

The sector divides into seven sub-sectors with materially different commercial dynamics, regulatory environments and candidate pools. Most businesses sit clearly in one; some — a diagnostics company with a software platform, or a care provider building a digital offer — straddle two, and the brief needs to say which one dominates.

Pharmaceuticals

Drug discovery, development and commercialisation. The segment ranges from large global groups with UK operations to a mid-market of specialty, generics and emerging pharma companies. Product-development cycles are long, the regulatory burden is heavy (MHRA in the UK, the EMA for the EU, the FDA for the US), and the business model is capital-intensive. Senior hiring usually weights scientific or clinical credibility alongside a commercial track record, and for commercial roles, direct experience of UK market access and NHS pricing.

Biotech

Earlier-stage drug discovery and development companies, often venture-backed or recently listed. The business model differs from established pharma: a narrower pipeline, value tied to clinical milestones, and a funding cycle that dictates the calendar. The quality of the senior team is one of the main things investors are backing. Senior hiring emphasises scientific credentials, prior biotech operating experience, and the ability to raise capital and communicate with specialist investors.

Medical devices

Surgical instruments, monitoring equipment, implantable devices, and capital equipment. The regulatory pathway is different from medicines — conformity assessment and UKCA or CE marking in Great Britain, the EU MDR for European market access, and FDA 510(k) or PMA routes in the US — and product cycles are typically shorter. Commercial dynamics differ too, with sales often running through hospital procurement, clinical champions and framework agreements rather than directly through payers.

Digital health

Software, AI, remote monitoring, telemedicine, digital therapeutics and health data platforms. Senior hiring here blends technology and product credentials with real healthcare domain knowledge: clinical safety, information governance, NHS procurement, and in some cases software regulated as a medical device. Strong candidates typically have substantive experience of both worlds; people who have only one tend to struggle in the other.

Diagnostics

Laboratory testing, imaging, in vitro diagnostics and genetic and genomic testing, covering both clinical-laboratory service businesses and diagnostic device manufacturers. The sub-sector expanded sharply during the pandemic and has since had to reset around routine clinical demand, which has made commercial and operational leadership hires particularly important.

Clinical research organisations and contract development

Service providers to pharma and biotech for clinical trial delivery, regulatory work, and contract development and manufacturing. The UK has an active mid-market of CROs and CDMOs. Leadership here is about operational delivery, quality systems, client management with sponsors, and capacity planning — a different profile from product-led companies.

Healthcare services

Care home operators, private hospital groups, primary care and community providers, occupational health, domiciliary care and NHS-adjacent service businesses. These are typically labour-intensive and payer-driven, with the regulatory focus on care quality, safety and the fitness of the people running the service. Workforce supply, local authority and NHS commissioning, and inspection outcomes shape almost every senior decision.

Regulatory dimensions

UK healthcare and life sciences senior hiring intersects with several regulatory frameworks that shape the role specification, the assessment and, in some cases, who is legally allowed to hold the job. The relevant regulators depend on the sub-sector, so the brief should name them explicitly.

MHRA (Medicines and Healthcare products Regulatory Agency)

The UK regulator for medicines, medical devices and clinical trials. Senior roles in pharma, biotech and medical devices need real familiarity with how the MHRA operates, and regulatory strategy is a board-level matter rather than a back-office function. The rules are still moving. New UK clinical trials regulations, signed into law in 2025, came into force on 28 April 2026, changing approval routes, transparency obligations and how sponsors work with the MHRA and research ethics committees. On the devices side, strengthened post-market surveillance requirements apply in Great Britain, and the longer-term framework for device regulation continues to develop. Candidates for regulatory, quality and clinical leadership should be able to talk specifically about how these changes affect the business they would be joining.

FDA, EMA and other international regulators

UK businesses with international product reach need senior leaders who have worked across more than one regulatory system — particularly the FDA for US-bound products and the EMA and EU notified bodies for European market access. A UK-only regulatory track record is often a gap for companies whose value case depends on a US launch.

NICE (National Institute for Health and Care Excellence)

Health technology assessment for the NHS in England. NICE appraisal outcomes determine whether, and on what terms, a new medicine or technology reaches NHS patients, so market access experience is central to commercial hiring for companies targeting the NHS.

CQC (Care Quality Commission)

The independent regulator of health and adult social care services in England. Providers carrying on regulated activities must register, and the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 set out requirements on the people running services — including the fit and proper persons requirement for directors and equivalents, and the requirements for registered managers. That makes background, conduct and track record checks a formal part of senior hiring at care providers, not just good practice. The CQC itself has been rebuilding its assessment approach following the critical independent review of its operations in 2024, and senior candidates in healthcare services should understand where inspection practice now stands.

HRA (Health Research Authority)

Oversees research governance and ethics in England and works alongside the MHRA on clinical trial approvals. Relevant for CRO, biotech and pharma leadership where clinical research is core to the business.

Policy and market changes shaping senior hiring

Beyond the regulators, three policy developments are changing what boards need from senior leaders in the sector, and strong candidates will expect a search firm to understand them.

The abolition of NHS England

In March 2025 the government announced that NHS England would be abolished and its functions brought into the Department of Health and Social Care. The Health Bill provides for NHS England’s functions to pass to the Secretary of State or to integrated care boards, with the department working through regional teams. For suppliers and service providers, that means a changing map of buyers, budget holders and decision-makers. Commercial, market access and public affairs leaders who understood the old structure need to show they can rebuild relationships in the new one.

The Life Sciences Sector Plan

The government’s Life Sciences Sector Plan, published in July 2025, sets an ambition for the UK to be the leading life sciences economy in Europe by 2030 and third globally by 2035, with actions on research and development, investment, advanced manufacturing and the adoption of innovation in the NHS. For hiring, the practical effects are in clinical trial speed, NHS adoption routes and manufacturing investment — areas where leaders with delivery experience are in demand.

Medicines pricing and VPAG

Branded medicines supplied to the NHS are covered by the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), under which companies make payments back to government on qualifying sales. The level of those payments was a source of serious industry concern in 2025 and was revised following the UK–US agreement on pharmaceutical pricing in December 2025, which also raised the thresholds NICE uses to judge the cost-effectiveness of new medicines. For pharma and biotech boards, pricing and access strategy now sits even closer to the CEO and CFO agenda, and commercial leaders need to be fluent in it.

The senior team in healthcare and life sciences firms

The shape of the senior team varies by sub-sector and stage, but seven roles recur as common appointments.

CEO

Needs sector experience on top of the standard CEO requirements of commercial leadership, board engagement and, where relevant, capital markets. Pharma and biotech CEOs usually come from senior commercial, development or general management roles within the sector; digital health CEOs may come from technology backgrounds but need demonstrable healthcare domain knowledge. Our guide to hiring a CEO covers the general process.

Chief Medical Officer

In pharma, biotech, medical devices and digital health, the CMO is the senior clinical leader — usually a qualified doctor with clinical and drug or device development experience — and should not be confused with a Chief Marketing Officer. The clinical CMO owns clinical strategy, leads regulatory engagement on clinical questions and carries the clinical credibility of the company’s products with regulators, investigators and investors. In digital health, the role often also covers clinical safety and governance.

Chief Scientific Officer

Appointed alongside or instead of a clinical CMO, particularly in pre-clinical biotech and emerging pharma. The CSO leads the science and the pipeline, and in early-stage companies is often a founder or the person investors most want to hear from.

CFO

Healthcare and life sciences CFOs need sector-specific experience: milestone-driven funding and capital structures in pharma and biotech, grant and R&D tax relief management, licensing and partnering economics, and listed-market experience where relevant. In healthcare services, the emphasis shifts to fee rates, occupancy, workforce cost and lender relationships. See our CFO recruitment service.

Chief Commercial Officer

Central in established pharma, biotech approaching launch, and medical devices. The CCO leads market access, payer and NHS relationships, pricing and commercial strategy. With NHS structures and pricing arrangements both changing, this is one of the roles where up-to-date UK market access experience matters most.

Head of Regulatory Affairs

The senior regulatory leader, typically reporting to the CEO or COO, with direct experience of engaging with the MHRA, FDA, EMA and notified bodies. This is the company’s senior interface with regulators and, at earlier-stage companies, often the person who decides whether a submission timetable is realistic.

Director of Quality Assurance

Quality leadership is a regulatory requirement in much of the sector, not a nice-to-have. In medicines manufacturing it links to GMP and the Qualified Person; in devices, to the quality management system and conformity assessment; in healthcare services, to clinical governance and inspection readiness. Our Director of Quality Assurance recruitment service covers these appointments.

Many businesses in the sector also need independent board members with clinical, regulatory or NHS experience; see our healthcare and life sciences non-executive recruitment page.

The candidate pool

The UK senior candidate pool in healthcare and life sciences is deep in sector knowledge but tight in most sub-sectors, and the best people are rarely on the market. Five pools recur.

Sitting senior executives at peer firms. The most common pool, and the one where sub-sector specificity matters most. A strong CEO at a large pharma company is a different proposition from a strong biotech CEO; a strong commercial leader in medical devices is different again from one in digital health.

Step-up candidates from larger global groups. The natural growth pool for CEO, CFO and CCO appointments at UK mid-market businesses: senior figures from large pharma or device groups moving into smaller companies with broader scope. The assessment question is whether they can operate without the infrastructure they are used to.

Cross-sub-sector candidates. Moves between sub-sectors — pharma to biotech is common, digital health to medical devices less so. These candidates can bring useful perspective, but the brief needs to be clear about which parts of their experience are expected to transfer.

Consulting and advisory transitions. Senior people from healthcare-focused consulting practices moving in-house, usually into commercial, strategy or transformation roles. Strong on analysis and NHS structures; the question is operating experience.

Clinical and scientific specialists with commercial credentials. Particularly for CMO and CSO roles: senior clinicians or scientists with substantive prior experience in pharma, biotech or devices. Clinical credibility alone is rarely enough at board level.

For some businesses — early-stage companies, or those between funding rounds — the right answer is an interim or part-time appointment rather than a permanent hire. Our interim executive recruitment service covers those mandates.

Compensation

Senior compensation in healthcare and life sciences tends to sit above general cross-sector benchmarks for comparable roles, reflecting the commercial complexity, regulatory exposure and tightness of the pool. The structure varies more by sub-sector and ownership than the headline base salary does:

• Mid-market pharma and biotech. Base salary is only part of the picture. Annual bonuses are often tied to clinical, regulatory and financing milestones, and equity participation can be the main economic driver, especially in venture-backed biotech.
• Listed pharma and medical devices. Packages follow listed-company norms, with long-term incentive plans approved by shareholders under the company’s remuneration policy and disclosed in the annual report.
• Digital health and growth-stage biotech. Packages are often weighted towards equity rather than cash. Strong candidates look hard at the cap table, liquidation preferences, vesting and the realistic path to an exit.
• Healthcare services. Typically more cash-weighted, with bonuses linked to financial performance, occupancy or activity, and quality and inspection outcomes. Private equity ownership brings management equity into play.

Benchmarks should come from sector-specific data for the relevant sub-sector and company size, not from cross-sector averages. For more on structures, see our Executive Compensation guide.

Common healthcare and life sciences search pitfalls

Six patterns recur in searches that stall or produce the wrong appointment.

• Insufficient sub-sector specificity in the brief. “Healthcare experience” is too broad to search against. Name the sub-sector, the regulators and the buyers.
• Underestimating the regulatory dimension. Strong candidates expect a search firm and a board to understand the regulatory position, including recent changes such as the new clinical trials regulations or NHS restructuring.
• Mixing scientific, clinical and commercial requirements. One person rarely excels at all three. Decide which the role is weighted towards and build the team around the gaps.
• Compensation anchored to cross-sector benchmarks. This leads to offers that miss, particularly where equity is the main part of the package.
• Underestimating the capital markets dimension. For listed, pre-IPO and venture-backed businesses, investor communication is a core part of the CEO and CFO roles.
• Cultural mismatch between sub-sectors. Candidates from large pharma, venture-backed biotech and NHS-facing services can look aligned on paper and work in very different ways.

How Exec Capital approaches healthcare and life sciences mandates

Exec Capital runs healthcare and life sciences executive search with the sub-sector specifics worked through at the brief stage: which regulators matter, who the buyers are, what stage the business is at, and what the board actually needs the new leader to do in the first year. Scientific, clinical, regulatory and commercial credentials are assessed with the same rigour we apply to any senior search, with sector-specific referencing and, where the regulations require it, fit and proper checks built in.

We work on a retained basis, with engagement running through to the candidate’s first day in role. Every search is run by our specialist team, with Adrian Lawrence FCA overseeing each mandate. For boards starting a senior search, building out a team for a growth-stage business, or working through whether the current team is right for the next phase, we start with a structured conversation about the brief.

Further reading

The related services and guides below cover the individual senior roles in more detail. For primary sources on the policy and regulatory points in this guide, see the government’s Life Sciences Sector Plan, the Health Bill fact sheets on the abolition of NHS England, the VPAG scheme documents, and the regulated activities regulations linked above. The MHRA, NICE, the CQC and the HRA each publish current guidance for organisations they regulate, and the ABPI and the BioIndustry Association publish industry commentary.

Frequently asked questions

Do healthcare executives need to be approved by a regulator before appointment?

Not in the way FCA-regulated senior managers are. However, CQC-registered providers must ensure their directors meet the fit and proper persons requirement and that registered managers meet the regulations, and some roles in medicines manufacturing, such as the Qualified Person, carry their own legal requirements.

Should a biotech appoint a Chief Medical Officer or a Chief Scientific Officer?

It depends on stage. Pre-clinical companies usually need a CSO leading the science; once the company moves into the clinic, a clinical CMO becomes important. Many companies end up needing both.

How has the abolition of NHS England affected commercial hiring?

It has changed who holds budgets and makes decisions, with functions moving to the Department of Health and Social Care and integrated care boards. Commercial and market access leaders need to show they understand the new structure, not just the old one.

Can a candidate move from pharma into digital health or medical devices?

Yes, but the brief should be clear about what is expected to transfer. Regulatory and commercial experience can carry across; selling models, product cycles and clinical safety requirements are often quite different.

Is an interim appointment sensible for a healthcare or life sciences business?

Often, yes — for example to cover a regulatory submission, a funding round, an inspection recovery or the gap before a permanent hire. The interim needs the same sub-sector fit as a permanent appointment.